Couverture de VerifiedRx

VerifiedRx

VerifiedRx

De : Vizient Center for Pharmacy Practice Excellence
Écouter gratuitement

Offres de saison | 0,99 € par mois pendant les 3 premiers mois

5,99 €/mois par la suite. Des conditions s’appliquent. Annulation mensuelle possible.
Delivering short doses of insight for hospitals’ frontline pharmacy professionals, the Vizient pharmacy team brings together experts to verify best practices for navigating today’s pharmacy practice challenges and accelerating career growth. It’s a prescription for success, delivered by the Vizient Center for Pharmacy Practice Excellence.Copyright 2026 All rights reserved. Economie Hygiène et vie saine Maladie et pathologies physiques Management Management et direction Science
Épisodes
  • Clinically Integrated Supply Chain: Pharmacy’s Opportunity to Lead

    Clinically Integrated Supply Chain: Pharmacy’s Opportunity to Lead
    Oct 27 2026

    A clinically integrated supply chain connects clinical evidence, utilization, operations, financial performance, and patient outcomes to help guide better health system supply chain decisions. Host Carolyn Liptak, is joined by Vizient colleagues Joel Hennenfent and Kersten Weber Tatarelis to discuss why pharmacy leaders are uniquely positioned to lead this work and expand their influence across the enterprise.

    Guest Speakers: Joel Hennenfent, PharmD, MBA, FASHP SVP &GM, Pharmacy Solutions Vizient

    Kersten Weber Tatarelis, PharmD, MBA, BCPS, FASHP, FACHE SVP, Pharmacy Spend Management Delivery Vizient

    Host: Carolyn Liptak, MBA, BS Pharm Pharmacy Executive Director, Regulatory Compliance Vizient Center for Pharmacy Practice Excellence

    Show Notes:

    [01:00]

    • What a clinically integrated supply chain is and how it connects clinical, financial, and operational decisions.
    • Why pharmacy is essential to managing advanced therapies, specialty medications, and biosimilars.

    [03:08]

    • The financial, reimbursement, workforce, and specialty pharmacy pressures facing pharmacy leaders.
    • Why strong contracts require clinical alignment and operational follow through.

    [04:56]

    • How pharmacy leaders are moving beyond traditional pharmacy responsibilities.
    • Why partnerships with finance, supply chain, and physician leaders matter.

    [06:20]

    • The expanding role of pharmacy leaders in site of care decisions, capital planning, and strategic growth.
    • Why pharmacy leaders should have a seat at the enterprise leadership table.

    [09:20]

    • How pharmacy can lead governance and value analysis through evidence based decisions.
    • The importance of reducing variation while allowing for individualized patient care.

    [11:15]

    • Why data alone does not change behavior.
    • How trust, transparency, and accountability support lasting improvement.

    [13:13]

    • The signs that an organization is ready for a clinically integrated supply chain.
    • Why meaningful change requires clear ownership, governance, and accountability.

    [14:24]

    • The business and financial skills pharmacy leaders need to develop.
    • How understanding revenue, reimbursement, and costs can strengthen enterprise leadership.

    [15:39]

    • Advice for pharmacy leaders pursuing broader health system roles.
    • The value of learning how other areas of the organization operate.

    [16:55]

    • How clinically integrated supply chain strategy can improve care and financial performance.
    • Why pharmacy should be viewed as a source of revenue and organizational value.

    [18:11]

    • Why pharmacy leaders should see themselves as healthcare executives.
    • How pharmacy can help shape clinical and financial strategy.

    Links and Resources:

    Vizient Clinically Integrated Supply Chain

    Subscribe Today!

    Apple Podcasts

    Spotify

    YouTube

    RSS Feed
    Afficher plus Afficher moins
    20 min
  • Advancing access to cell and gene therapies through the Advanced Therapeutics Alliance

    Advancing access to cell and gene therapies through the Advanced Therapeutics Alliance
    Oct 13 2026
    Advanced therapeutics are expanding treatment possibilities for patients while creating new operational, financial and access challenges for health systems. Host Carolyn Liptak joins Elizabeth Oyekan, Lynn Eichenbacher and Carina Dolan to discuss the Advanced Therapeutics Alliance, a provider-led collaborative that brings together healthcare providers, payers, pharmaceutical companies and other industry partners to improve access to cell and gene therapies through shared knowledge, coordinated action and cross-sector collaboration. To join the alliance, visit Advanced Therapeutics Alliance. Guest Speakers: Elizabeth Oyekan, PharmD, FCSHP, CPHQ, CPEL President FiveTwo Health Partners Lynn Eschenbacher, PharmD, MBA, FASHP, CPEL Chief Pharmacy Officer and Strategy Officer PharmaForce Carina Dolan, PharmD, MS Pharm, BCOP AVP, Market Insights & Forecasting Vizient Clinical Spend Management Host: Carolyn Liptak, MBA, BS Pharm Pharmacy Executive Director, Regulatory Compliance Vizient Center for Pharmacy Practice Excellence Show Notes: [01:07] How fragmented systems can create delays for patients The development of the Advanced Therapeutics Alliance and its focus on access, sustainability, and equity [02:40] The challenges created by single case agreements, payer requirements, and manual processesThe value of health systems sharing solutions instead of addressing similar challenges independently [04:14] Common concerns across health systems related to reimbursement, infrastructure, patient access, payer variability, and long term sustainability The importance of connecting organizations that are facing similar challenges Why improving access to advanced therapies requires collaboration across the healthcare ecosystem [06:06] Pharmacy’s role across clinical care, operations, finance, regulatory requirements, and patient support The importance of involving pharmacy leaders early in the development Opportunity for pharmacy to help lead this work while bringing the right partners to the table [08:48] The need for collaboration among pharmacy, physicians, nursing, finance, revenue cycle, administration, manufacturers, payers, and patient advocacy organizations How pharmacy leaders are helping their organizations establish the policies, resources, and processes needed to support advanced therapies The Alliance’s role in extending collaboration beyond individual health systems [10:33] What distinguishes the Advanced Therapeutics Alliance from other efforts in this space The focus on turning shared experiences into practical action [11:23] How greater understanding across the healthcare ecosystem can support scalable and sustainable processesThe role of Vizient in connecting providers, manufacturers, payers, and other partners [12:26] How organizations can bring forward their priorities, experiences, challenges, and ideasThe goal of translating existing knowledge into action that can be shared across organizations [13:05] The Alliance’s mission to increase patient access to life changing therapies The need to build sustainable processes that can support the growing number of advanced therapies [14:48] The value of joining the Alliance while its work groups and resources are being established How pharmacy leaders can learn from peers and bring new perspectives back to their organizations [16:32] The importance of sharing real world experiences and contributing to collaborative solutions The call for stakeholders across the cell and gene therapy ecosystem to help improve access and sustainability for patients Links and Resources: Advanced Therapeutics AllianceVizient Cell & Gene TherapyAdvancing cell, gene, and specialty therapies requires enterprise transformation, Jun 18, 2026.For more information: Vizient pharmacy questions mailbox Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed
    Afficher plus Afficher moins
    18 min
  • Don't set it and forget it: Managing biosimilar formularies dynamically

    Don't set it and forget it: Managing biosimilar formularies dynamically
    Sep 29 2026

    Strategic biosimilar optimization can help health systems evaluate medication choices through a broader clinical, operational, financial, and payer-focused lens. Dr. Jerry Rebo from Novant Health joins host Heather Pace to discuss a structured quarterly process for reviewing biosimilar performance, monitoring payer preferences, identifying denial trends, and supporting informed therapy decisions. He shares practical guidance for health systems, building a similar approach with existing resources.

    Guest: Jerry Rebo, PharmD, MBA, BCPS, BCCCPS, D-PLA Director of Value & Outcomes Novant Health

    Host: Heather Pace, PharmD Senior Clinical Manager, Ambulatory Center for Pharmacy Practice Excellence, Clinical Spend Management Vizient

    Show Notes:

    [00:55]

    • The challenges of managing biosimilars across clinical care, clinic operations, reimbursement, payer contracting, prior authorization, and patient experience.
    • The factors Novant Health considers when evaluating biosimilar products and therapeutic classes.

    [01:51]

    • Novant Health’s structured four-week review process, beginning with data collection from studies, reimbursement reports, payer policies, denial trends, and margin analysis.
    • The role of therapeutic class reviews, clinical feedback, operational considerations, and financial performance in developing quarterly recommendations.

    [03:27]

    • The purpose of a biosimilar payer table and the way it tracks formulary updates, payer preferences, documentation requirements, and denial trends.
    • How payer information supports communication among medical teams, authorization teams, pharmacy teams, and informatics partners.

    [04:52]

    • The difference between responding to individual denials and monitoring denial patterns over time.
    • The value of identifying whether denials are connected to internal operational issues or changes in payer policies and plans.

    [06:49]

    • How expected payment rates are calculated by comparing actual reimbursement with billed amounts.
    • The importance of reviewing reimbursement performance regularly so product recommendations can be updated as conditions change.

    [07:56]

    • The challenges of identifying opportunities for optimization across different therapeutic classes and payer types.
    • Why Medicare Advantage plans require additional review since their preferences may differ from standard Medicare formularies.

    [09:36]

    • The value of breaking down organizational silos and bringing pharmacy, revenue cycle, clinical, operational, and administrative experts together.
    • How a systematic biosimilar review process may support future medication management efforts involving biologics, cell therapies, and gene therapies.

    [10:53]

    • Practical advice for health systems that want to begin a biosimilar optimization process with limited resources or staffing.
    • The importance of connecting with colleagues, learning from related initiatives, and mapping existing workflows before building a new process.

    [12:02]

    • Opportunities to use automation and technology to reduce manual data preparation.
    • The potential for more efficient tools to give teams additional time for analysis, recommendations, and implementation.

    [13:16]

    • The importance of building relationships across the health system to solve shared problems.
    • The role of cross-functional collaboration in supporting successful biosimilar management.

    Links and Resources:

    Vizient 2026 Connections Summit (poster presentations will be available for viewing on Oct 7)

    Subscribe Today!

    Apple Podcasts

    Spotify

    YouTube

    RSS Feed
    Afficher plus Afficher moins
    14 min
adbl_web_anon_alc_button_suppression_t1
Aucun commentaire pour le moment